Twist Bioscience Fiscal Q2 Revenues Rise 19 Percent
The synthetic biology company raised its full-year fiscal 2026 revenue outlook to between $442 million and $447 million, representing growth of 17 to 19 percent.
Twist Bioscience said before the market opened on Monday that its fiscal second quarter revenues rose 19 percent year over year.
The South San Francisco-based synthetic biology firm reported revenue of $110.7 million, up from $92.8 million a year ago.
“We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth,” CEO Emily Leproust said in a statement. “We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio.”
Separately, Twist announced the launch of an early access program for the manufacturing of complex genes. “We’ve added complex sequences to our gene synthesis offering and expanded our length up to 7,000 base pairs,” Leproust said in a statement. “With reliable complexity at scale, we expect to be able to accept about 99.5 percent of clonal genes sequences sent to us by our customers and 99.9 percent of all DNA products.”
NGS Applications revenue grew 12 percent to $57.4 million from $51.1 million a year ago, while DNA Synthesis and Protein Solutions revenue grew 28 percent to $53.3 million from $41.6 million a year ago.
The company’s net loss for the quarter was $44.0 million, or $.71 per share, compared to a loss of $39.3 million, or $.66 per share, in fiscal Q2 2025.
Twist’s R&D expenses fell 18 percent to $19.7 million from $23.9 million a year ago while SG&A expenses increased 20 percent to $76.1 million from $63.7 million a year ago.
Twist reached a settlement in principle in a securities class action for approximately $17.1 million. The company booked $7.2 million in litigation settlement costs, net of recoveries, in the quarter.
As of March 31, Twist had $122.7 million in cash and cash equivalents and $49.0 million in short-term investments.
Twist raised its full-year fiscal 2026 revenue outlook to between $442 million and $447 million, representing growth of 17 to 19 percent, from prior guidance of $435 million to $440 million. For fiscal Q3 2026, Twist guided to revenue of approximately $114 million to $115 million, growth of approximately 19 percent year over year at the midpoint.